I en dobbeltblind, sammenlignende undersøgelse af kroniske hepatitis B patienter med lamivudin- resistent HBV (n=58) var der ingen median reduktion i HBV- DNA fra baseline efter 48 ugers behandling med lamivudin.
In a double-blind comparative study in chronic hepatitis B patients with lamivudine-resistant HBV (n=58), there was no median reduction in HBV DNA from baseline after 48 weeks of treatment with lamivudine.